Celastrol inhibits breast cancer cell invasion via suppression of NF-κb-mediated matrix metalloproteinase-9 expression

Cellular Physiology and Biochemistry

Volumn 28, Issue 2, 2011, Pages 175-184

  Kim, Yoonseo ^a   Kang, Hyereen ^a   Jang, Sung Wuk ^a   Ko, Jesang ^a  

^a Korea University   (South Korea)

Author keywords

Breast cancer; Celastrol; Cell invasion; Cell migration; MMP 9

Indexed keywords

ANTINEOPLASTIC AGENT; CELASTROL; GELATINASE B; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; BREAST CANCER; CANCER INHIBITION; CANCER INVASION; CELL ASSAY; CELL CYCLE G1 PHASE; CELL NUCLEUS; CELL STRAIN MCF 7; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DNA BINDING; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LOW DRUG DOSE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 80052081077     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000331729     Document Type: Article

References (29)

1. Woessner JF: Matrix metalloproteinases and their inhibitors in connective tissue remodeling. Faseb J 1991;5:2145-2154.
2. Rao JS: Molecular mechanisms of glioma invasiveness: The role of proteases. Nat Rev Cancer 2003;3:489-501. (Pubitemid 37328837)
3. Chambers AF, Matrisian LM: Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270. (Pubitemid 27371946)
4. Nabeshima K, Inoue T, Shimao Y, Sameshima T: Matrix metalloproteinases in tumor invasion: Role for cell migration. Pathol Int 2002;52:255-264. (Pubitemid 34587810)
5. Stetler-Stevenson WG, Hewitt R, Corcoran M: Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin Cancer Biol 1996;7:147-154. (Pubitemid 26179261)
6. Adam L, Vadlamudi R, Kondapaka SB, Chernoff J, Mendelsohn J, Kumar R: Heregulin regulates cytoskeletal reorganization and cell migration through the p21-activated kinase-1 via phosphatidylinositol-3 kinase. J Biol Chem 1998;273:28238-28246. (Pubitemid 28496122)
7. Sawicki G, Radomski MW, Winkler-Lowen B, Krzymien A, Guilbert LJ: Polarized release of matrix metalloproteinase-2 and-9 from cultured human placental syncytiotrophoblasts. Biol Reprod 2000;63:1390-1395.
8. Liu JF, Crepin M, Liu JM, Barritault D, Ledoux D: Fgf-2 and tpa induce matrix metalloproteinase-9 secretion in mcf-7 cells through pkc activation of the ras/erk pathway. Biochem Biophys Res Commun 2002;293:1174-1182. (Pubitemid 34681065)
9. Kondapaka SB, Fridman R, Reddy KB: Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (mmp-9) in human breast cancer cells. Int J Cancer 1997;70:722-726. (Pubitemid 27158453)
10. Sato H, Seiki M: Regulatory mechanism of 92 kda type iv collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 1993;8:395-405. (Pubitemid 23073756)
11. Sato H, Kita M, Seiki M: V-src activates the expression of 92-kda type iv collagenase gene through the ap-1 site and the gt box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 1993;268:23460-23468. (Pubitemid 23328072)
12. Takahra T, Smart DE, Oakley F, Mann DA: Induction of myofibroblast mmp-9 transcription in three-dimensional collagen i gel cultures: Regulation by nfkappab, ap-1 and sp1. Int J Biochem Cell Biol 2004;36:353-363. (Pubitemid 37487769)
13. Karin M, Ben-Neriah Y: Phosphorylation meets ubiquitination: The control of nf-[kappa]b activity. Annu Rev Immunol 2000;18:621-663. (Pubitemid 30365393)
14. Park SK, Hwang YS, Park KK, Park HJ, Seo JY, Chung WY: Kalopanaxsaponin a inhibits pma-induced invasion by reducing matrix metalloproteinase-9 via pi3k/akt-and pkcdelta-mediated signaling in mcf-7 human breast cancer cells. Carcinogenesis 2009;30:1225-1233.
15. Petronelli A, Pannitteri G, Testa U: Triterpenoids as new promising anticancer drugs. Anticancer Drugs 2009;20:880-892.
16. Calixto JB, Campos MM, Otuki MF, Santos AR: Anti-inflammatory compounds of plant origin. Part ii. Modulation of pro-inflammatory cytokines, chemokines and adhesion molecules. Planta Med 2004;70:93-103. (Pubitemid 38299768)
17. Sethi G, Ahn KS, Pandey MK, Aggarwal BB: Celastrol, a novel triterpene, potentiates tnf-induced apoptosis and suppresses invasion of tumor cells by inhibiting nf-kappab-regulated gene products and tak1-mediated nf-kappab activation. Blood 2007;109:2727-2735. (Pubitemid 46482064)
18. Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N: Apoptosis induction in hl-60 cells and inhibition of topoisomerase ii by triterpene celastrol. Biosci Biotechnol Biochem 2003;67:1883-1887. (Pubitemid 39251707)
19. Huang Y, Zhou Y, Fan Y, Zhou D: Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing vegfr expression. Cancer Lett 2008;264:101-106.
20. Yang H, Chen D, Cui QC, Yuan X, Dou QP: Celastrol, a triterpene extracted from the chinese "Thunder of god vine," Is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res 2006;66:4758-4765.
21. Jang SY, Jang SW, Ko J: Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor alpha. Cancer Lett 2011;300:57-65.
22. Lee JH, Koo TH, Yoon H, Jung HS, Jin HZ, Lee K, Hong YS, Lee JJ: Inhibition of nf-kappa b activation through targeting i kappa b kinase by celastrol, a quinone methide triterpenoid. Biochem Pharmacol 2006;72:1311-1321. (Pubitemid 44572192)
23. Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR: Gene expression signature-based chemical genomic prediction identifies a novel class of hsp90 pathway modulators. Cancer Cell 2006;10:321-330. (Pubitemid 44512193)
24. Magnani M, Crinelli R, Bianchi M, Antonelli A: The ubiquitin-dependent proteolytic system and other potential targets for the modulation of nuclear factor-kb (nf-kb). Curr Drug Targets 2000;1:387-399.
25. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D: A novel hsp90 inhibitor to disrupt hsp90/cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 2008;7:162-170.
26. Hanemaaijer R, Verheijen JH, Maguire TM, Visser H, Toet K, McDermott E, O'Higgins N, Duffy MJ: Increased gelatinase-a and gelatinase-b activities in malignant vs. Benign breast tumors. Int J Cancer 2000;86:204-207. (Pubitemid 30180815)
27. Scorilas A, Karameris A, Arnogiannaki N, Ardavanis A, Bassilopoulos P, Trangas T, Talieri M: Overexpression of matrixmetalloproteinase-in human breast cancer: A potential favourable indicator in node-negative patients. Br J Cancer 2001;84:1488-1496. (Pubitemid 32579341)
28. Han SY, Lee MS, Kim HR, Baek SH, Ahn DH, Chae HS, Erickson RH, Sleisenger MH, Kim YS: Phorbol 12-myristate 13-acetate induces alteration in mucin gene expression and biological properties of colon cancer cells. Int J Oncol 2000;17:487-494.
29. Lin CW, Shen SC, Hou WC, Yang LY, Chen YC: Heme oxygenase-1 inhibits breast cancer invasion via suppressing the expression of matrix metalloproteinase-9. Mol Cancer Ther 2008;7:1195-1206.